Responses
Regular and Young Investigator Award Abstracts
Clinical Trials In Progress
627 Oral administration of MRx0518 in treatment-naïve cancer patients is associated with compositional taxonomic and metabolomic changes indicative of anti-tumorigenic efficacy
Compose a Response to This Article
Other responses
No responses have been published for this article.